The estimated Net Worth of Michael W Rogers is at least 748 千$ dollars as of 21 June 2019. Mr. Rogers owns over 6,667 units of Akebia Therapeutics stock worth over 171,600$ and over the last 11 years he sold AKBA stock worth over 405,911$. In addition, he makes 170,966$ as Independent Director at Akebia Therapeutics.
Sign up
Mr. Rogers AKBA stock SEC Form 4 insiders trading
Michael has made over 7 trades of the Akebia Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 6,667 units of AKBA stock worth 9,600$ on 21 June 2019.
The largest trade he's ever made was exercising 100,000 units of Akebia Therapeutics stock on 15 November 2018 worth over 113,000$. On average, Michael trades about 3,561 units every 46 days since 2013. As of 21 June 2019 he still owns at least 119,167 units of Akebia Therapeutics stock.
You can see the complete history of Mr. Rogers stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Rogers biography
Michael W. Rogers serves as Independent Director of the Company. Mr. Rogers had served as Chairman of the Board of Directors of Keryx from September 2017 until completion of the Merger, and a member of the Board of Directors of Keryx from March 2016 until completion of the Merger. He served as Chief Financial Officer of Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, from November 2017 until October 2019. Prior to Aerpio, Mr. Rogers was Chief Financial Officer of Acorda Therapeutics, Inc. (Nasdaq: ACOR), a biotechnology company developing and commercializing therapies to treat neurological disorders, from October 2013 to October 2016. From 1999 to 2009, Mr. Rogers was the Chief Financial Officer of Indevus Pharmaceuticals, Inc. until the company’s sale to Endo Pharmaceuticals, Inc. He also served as Chief Financial Officer at BG Medicine, Inc. (OCTCMKTS: BGMD), Advanced Health Corporation and Autoimmune Inc. Prior to his roles as chief financial officer, Mr. Rogers was an investment banker at Lehman Brothers and PaineWebber, where he focused on life sciences companies. He previously served on the Board of Directors for EyePoint Pharmaceuticals (Nasdaq: EYPT), formerly pSivida Corp. Mr. Rogers received his B.A. from Union College and an M.B.A. from the Darden School of Business at the University of Virginia.
What is the salary of Michael Rogers?
As the Independent Director of Akebia Therapeutics, the total compensation of Michael Rogers at Akebia Therapeutics is 170,966$. There are 10 executives at Akebia Therapeutics getting paid more, with John Butler having the highest compensation of 4,316,960$.
How old is Michael Rogers?
Michael Rogers is 60, he's been the Independent Director of Akebia Therapeutics since 2018. There are 3 older and 15 younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics Inc. is Adrian Adams, 69, who is the Independent Chairman of the Board.
What's Michael Rogers's mailing address?
Michael's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC., 245 FIRST ST., CAMBRIDGE, MA, 02142.
Insiders trading at Akebia Therapeutics
Over the last 11 years, insiders at Akebia Therapeutics have traded over 3,056,393$ worth of Akebia Therapeutics stock and bought 2,141,907 units worth 27,915,834$ . The most active insiders traders include Holdings A/S Novo、Muneer A Satter、Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of 43,534$. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth 15,140$.
What does Akebia Therapeutics do?
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
What does Akebia Therapeutics's logo look like?
Complete history of Mr. Rogers stock trades at Acorda Therapeutics Inc、Akebia Therapeutics、EyePoint Pharmaceuticals Inc、Aerpio Pharmaceuticals Inc、Aravive Inc
Akebia Therapeutics executives and stock owners
Akebia Therapeutics executives and other stock owners filed with the SEC include:
-
John Butler,
President, Chief Executive Officer, Director -
Michel Dahan,
Chief Operating Officer, Senior Vice President -
Nicole Hadas,
Senior Vice President, Chief Legal Officer, Corporate Secretary -
Dell Faulkingham,
Senior Vice President, Chief Commercial Officer -
John P. Butler MBA,
CEO, Pres & Director -
Dr. Steven Keith Burke,
Sr. VP of R&D and Chief Medical Officer -
Dell Faulkingham,
Sr. VP & Chief Commercial Officer -
Michel Dahan,
Sr. VP & COO -
Jason A. Amello,
Exec. Officer -
Adrian Adams,
Independent Chairman of the Board -
Michael Rogers,
Independent Director -
Maxine Gowen,
Independent Director -
Michael Heffernan,
Independent Director -
Cynthia Smith,
Independent Director -
Mark Enyedy,
Independent Director -
Steven Gilman,
Independent Director -
Kristen Sheppard,
Vice President, Investor Relations -
Myles Wolf,
Independent Director -
Steven Burke,
Senior Vice President, Chief Medical Officer -
David Spellman,
Chief Financial Officer, Senior Vice President, Treasurer -
Douglas Jermasek M.B.A.,
VP of Marketing & Strategy -
Mercedes Carrasco,
Director of Corp. Communications -
Nicole R. Hadas,
Sr. VP, Chief Legal Officer & Sec. -
Violetta Cotreau,
Sr. VP, Chief Accounting Officer & Principal Accounting Officer -
Scott A Canute,
-
Duane Nash,
Director -
Ronald C Jr Renaud,
Director -
Muneer A Satter,
Director -
Michael D. Clayman,
Director -
Bradley Maroni,
SVP & Chief Medical Officer -
Anupam Dalal,
Director -
Michael S Wyzga,
Director -
Rita Jain,
SVP, Chief Medical Officer -
Karen L Tubridy,
SVP, Chief Development Officer -
Leanne M Zumwalt,
-
Ron Frieson,
-
Jodie Pope Morrison,
-
Robert Shalwitz,
Chief Medical Officer -
Bioventures Ltd Novartis,
10% owner -
Holdings A/S Novo,
10% owner -
Violetta Cotreau,
SVP, Chief Accounting Officer -
Jason Amello,
SVP, CFO & Treasurer -
Ellen Snow,
SVP, CFO and Treasurer -
Nicholas Grund,
Chief Commercial Officer -
Richard C Malabre,
Chief Accounting Officer -
Erik Ostrowski,
SVP, CFO, CBO & Treasurer